Company / Operating Income
Serina Therapeutics, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$24.0M
FY2025
5-year range
-$24.0M / -$3.1M
FY2021-FY2025
Trend
-667.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed -668% YoY in FY2025, a notable deviation from the 6-year average annual change of -96%.
Based on SEC 10-K filings.
-$24M in FY2025.
Declined from -$3M to -$24M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 667.7% year-over-year.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$24.0M | -667.7% |
| FY2024 | -$3.1M | +0.0% |
| FY2023 | -$3.1M | +55.1% |
| FY2022 | -$7.0M | +12.1% |
| FY2021 | -$7.9M | +36.8% |
| FY2020 | -$12.6M | -11.7% |
| FY2018 | -$11.2M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026